Aptose Biosciences Inc. (APTOF)
OTCMKTS · Delayed Price · Currency is USD
1.640
+0.040 (2.50%)
At close: Jan 23, 2026
Aptose Biosciences Employees
Aptose Biosciences had 13 employees as of December 31, 2024. The number of employees decreased by 23 or -63.89% compared to the previous year.
Employees
13
Change (1Y)
-23
Growth (1Y)
-63.89%
Revenue / Employee
n/a
Profits / Employee
-$1,484,154
Market Cap
4.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 13 | -23 | -63.89% | 13 | 0 |
| Dec 31, 2023 | 36 | 0 | - | 35 | 1 |
| Dec 31, 2022 | 36 | -6 | -14.29% | 35 | 1 |
| Dec 31, 2021 | 42 | 1 | 2.44% | 41 | 1 |
| Dec 31, 2020 | 41 | 8 | 24.24% | 39 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Clearside Biomedical | 32 |
| Vaccinex | 27 |
| Brainstorm Cell Therapeutics | 27 |
| Mosaic ImmunoEngineering | 8 |
| AXIM Biotechnologies | 7 |
| Bioxytran | 3 |
Aptose Biosciences News
- 5 weeks ago - Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC - GlobeNewsWire
- 7 weeks ago - Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations - GlobeNewsWire
- 2 months ago - Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical - GlobeNewsWire
- 2 months ago - Aptose Reports Third Quarter 2025 Results - GlobeNewsWire
- 3 months ago - Aptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML - GlobeNewsWire
- 5 months ago - Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor - GlobeNewsWire
- 5 months ago - Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial - GlobeNewsWire
- 5 months ago - Aptose Reports Second Quarter 2025 Results - GlobeNewsWire